The Oxford / AstraZeneca Covid-19 vaccine does not appear to provide protection against mild and moderate disease caused by the first viral variant identified in South Africa, according to a study scheduled to be published on Monday.
Although more than 2,000 patients have never died or been hospitalized in this study, findings that have not yet been peer-reviewed could complicate the competition to deploy vaccines when new strains emerge. ..
According to a randomized, double-blind study confirmed by the Financial Times, in both human and vaccinated human blood studies, Jab was significantly against the predominant 501Y.V2 virus variant in South Africa. Showed reduced efficacy.
“Two-dose regimen [the vaccine] Showed no protection against mild to moderate Covid-19 [the South African variant]The study states that its efficacy against severe Covid-19, hospitalization and death has not yet been determined.
The so-called Kent mutant, which Oxford University said on Friday as vulnerable to vaccines, is as sensitive to vaccines as older variants of the virus and has become a mutant that contributes to the Covid-19 surge in Brazil and South Africa. Acquired an existing E484K mutation. ..
Due to the relatively small sample size, there are some caveats to the survey. The study, led by the University of the Witwatersland and the University of Oxford in South Africa, enrolled 2,026 HIV-negative individuals with a median age of 31 years. Half of the group received at least one placebo and the other half received at least one dose. vaccine.
Tulio de Oliveira, head of South Africa’s genome surveillance network, told the Financial Times that the findings were “a wake-up call to control the virus and increase its response to Covid-19 worldwide.”
Health officials around the world want vaccines to reduce or completely eliminate the burden of hospitalization and ease blockades.
Although important, avoiding symptomatological but mild infections that do not progress to hospitalization is relatively non-urgent.
According to data from other studies, the vaccine still appears to be completely effective in preventing hospitalization and mortality caused by other variants of the coronavirus.
AstraZeneca initially declined to comment. He later stated that given that most of the participants were young and healthy adults, the vaccine’s effectiveness against serious illness and hospitalization caused by South African variants could not be adequately identified. ..
“Our vaccine because neutralizing antibody activity is comparable to other Covid-19 vaccines that have shown activity against more serious diseases, especially when the dosing interval is optimized for 8-12 weeks. I am confident that it can protect against serious illness. ” He added that other immune responses, such as T cells, may protect the body from the disease. Early data stated that these reactions “potentially remain intact” for South African variants.
The vaccine has begun to be applied to the mutant in Oxford, and clinical development is progressing rapidly, “ready for fall delivery,” he said. [if] necessary”.
Oxford declined to comment on the findings, saying it is working with partners around the world, including South Africa, to assess the effects of the new mutant on the first-generation Covid vaccine.
“Oxford is working with AstraZeneca to optimize the pipeline needed when strain changes are needed,” said the university. “This is the same problem faced by all vaccine developers and we will continue to monitor the emergence of new mutants that occur in preparation for future strain changes.”
The University of the Witwatersrand did not respond to requests for comment. The South African Ministry of Health did not immediately respond to requests for comment.
All Covid-19 vaccines to date have largely countered the B.1.1.7 mutants that emerged in the United Kingdom, but strains that originated in South Africa are even more worried.Both Johnson & Johnson And Novavax Clinical trials conducted in South Africa have stated that their vaccine is less effective against strains. In the trial, both vaccines provided complete protection against serious illness and death associated with Covid-19.
Modana says it will be Test booster shots Vaccines represcribed to target South African variants have been shown to be significantly less effective after studies have shown.
BioNTech / Pfizer stated that the vaccine was slightly less effective in laboratory studies using pseudoviruses with some mutations from the 501Y.V2 variant, but published test results for the variant itself. not.
The predominant 501Y.V2 variant in South Africa has recently been discovered in countries around the world, including the United States and the United Kingdom.
Last week, South Africa received one million doses of AstraZeneca vaccine, the first Covid-19 vaccine to arrive in the country, as part of a 1.5 million dose order from the Indian Serum Institute.
Oxford / AstraZeneca Covid Jab is much less effective against South African strains, studies show
https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36 Oxford / AstraZeneca Covid Jab is much less effective against South African strains, studies show